Aurobindo Pharma Q1

Cons PAT at Rs 519 cr vs Rs 585 cr, down 11.3% YoY

Cons sales at Rs 3,678.8 cr vs Rs3,767 cr, down 2.3% YoY

Cons EBITDA at Rs 842 cr vs Rs 889 cr YoY

Cons EBITDA margins at 22.9% vs 23.6% YoY